Latest Industry Insights

With growing sustainability demands, companies are looking for ways to demonstrate their green credentials. We spoke to Dr. Michael Frank to find out what ACT accreditation means for a company and why he thinks schemes like this are so important.

This article discusses how the culture of canine-derived organoid lines can be used to make meaningful observations in the emerging field of comparative oncology, prompting the next revolution in animal and human cancer studies.

HPLC system manufacturers have been striving to improve usability, accessibility and help users improve their experimental outcomes. And what better way to do that than to involve the users themselves in that development process.

We spoke with Bio-Rad’s Justin Barker to discover some of the challenges associated with gene expression analysis in oncology and learn about technology developments in this field.

We spoke to Prof. Oscar Ces, head of the Department of Chemistry at Imperial College London (ICL), to find out about the evolution of ICL’s White City Campus, the Agilent Measurement Suite and what it means for scientists across the board.

This article discusses the methodology of using common archived biospecimens for RNA sequencing in oncology applications, such as tumor profiling, introducing challenges and innovative solutions.

Hans van der Voorn tells us about some of the recent progress in the extracellular vesicle-based diagnostics and therapeutics landscape, particularly the need for industrial-scale EV isolation workflows.

Cutting-edge mass spectrometry proteomics technologies are accelerating the discovery and validation of novel targets in cancer, opening up new avenues for next-generation cancer therapeutics.

Hear how the capabilities of mass spectrometry (MS)-based proteomics are proving themselves in drug development and discovery and what this means for those working in oncology.

At AACR 2023, Technology Networks spoke with Dr. Mark Garner, global cancer segment market manager at Agilent Technologies, to learn how the new SureSelect Cancer CGP assay is empowering the cancer research field.